Mayne Pharma launches another generic oral contraceptive
Retrieved on:
Thursday, March 4, 2021
This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN24 FE, ORTHO CYCLENand ORTHO TRI-CYCLEN.
Key Points:
- This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN24 FE, ORTHO CYCLENand ORTHO TRI-CYCLEN.
- Mayne Pharma's CEO Scott Richards said, "We are very pleased to expand our Women's Health portfolio which now covers ~80% of Obstetrician/Gynaecologist oral contraceptive prescription volumes[1] and includes 24 marketed branded generic contraceptives.
- Mayne Pharma is committed to helping meet the needs of women in the US by providing cost effective, high-quality and novel contraceptive options.
- "In addition, Mayne Pharma has four women's health pipeline products pending at the FDA including the novel combined oral contraceptive NEXTSTELLIS (E4/DRSP) and a generic version of NUVARING.